Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Black Diamond Therapeutics (BDTX) Income from Continuing Operations (2018 - 2025)

Black Diamond Therapeutics' Income from Continuing Operations history spans 6 years, with the latest figure at 16426000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 7.25% year-over-year to 16426000.0; the TTM value through Dec 2025 reached 16583000.0, up 121.65%, while the annual FY2025 figure was 16583000.0, 121.65% up from the prior year.
  • Income from Continuing Operations reached 16426000.0 in Q4 2025 per BDTX's latest filing, down from 9814000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 55125000.0 in Q1 2025 to a low of 34588000.0 in Q3 2021.
  • Average Income from Continuing Operations over 3 years is 14357454.55, with a median of 17710000.0 recorded in 2024.
  • Peak YoY movement for Income from Continuing Operations: tumbled 143.6% in 2021, then soared 381.12% in 2025.
  • A 3-year view of Income from Continuing Operations shows it stood at 34588000.0 in 2021, then soared by 48.8% to 17710000.0 in 2024, then grew by 7.25% to 16426000.0 in 2025.
  • Per Business Quant, the three most recent readings for BDTX's Income from Continuing Operations are 16426000.0 (Q4 2025), 9814000.0 (Q3 2025), and 12302000.0 (Q2 2025).